CU20110214A7 - Piperidinas sustituidas - Google Patents

Piperidinas sustituidas

Info

Publication number
CU20110214A7
CU20110214A7 CU20110214A CU20110214A CU20110214A7 CU 20110214 A7 CU20110214 A7 CU 20110214A7 CU 20110214 A CU20110214 A CU 20110214A CU 20110214 A CU20110214 A CU 20110214A CU 20110214 A7 CU20110214 A7 CU 20110214A7
Authority
CU
Cuba
Prior art keywords
substituted
piperidins
diseases
prophylaxis
treatment
Prior art date
Application number
CU20110214A
Other languages
English (en)
Other versions
CU24011B1 (es
Inventor
Kersten Matthias Gericke
Grande Yolanda Cancho
Katja Zimmermann
Anja Buchmueller
Dirk Heimbach
Eckhard Bender
Mark Jean Gnoth
Mario Jeske
Susanne Roehrig
Christoph Gerdes
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20110214A7 publication Critical patent/CU20110214A7/es
Publication of CU24011B1 publication Critical patent/CU24011B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención se refiere a piperidinas sustituidas, a procedimientos para su preparación, al uso de las mismas para el tratamiento y/o profilaxis de enfermedades y al uso de las mismas para la producción de medicamentos para el tratamiento y/o profilaxis de enfermedades, especialmente de enfermedades cardiovasculares y enfermedades tumorales.
CU2011000214A 2009-05-27 2011-11-25 Piperidinas 2-fenil-5-(1,2,4-oxadiazol-5-il) sustituidas CU24011B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009022894A DE102009022894A1 (de) 2009-05-27 2009-05-27 Substituierte Piperidine
PCT/EP2010/003024 WO2010136138A1 (de) 2009-05-27 2010-05-18 Substituierte piperidine

Publications (2)

Publication Number Publication Date
CU20110214A7 true CU20110214A7 (es) 2012-03-15
CU24011B1 CU24011B1 (es) 2014-06-27

Family

ID=42537882

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000214A CU24011B1 (es) 2009-05-27 2011-11-25 Piperidinas 2-fenil-5-(1,2,4-oxadiazol-5-il) sustituidas

Country Status (28)

Country Link
US (3) US8440657B2 (es)
EP (1) EP2435431A1 (es)
JP (1) JP5728687B2 (es)
KR (1) KR20120024652A (es)
CN (1) CN102482270B (es)
AR (1) AR076709A1 (es)
AU (1) AU2010252339B2 (es)
BR (1) BRPI1012775A2 (es)
CA (1) CA2763386A1 (es)
CO (1) CO6470822A2 (es)
CR (1) CR20110627A (es)
CU (1) CU24011B1 (es)
DE (1) DE102009022894A1 (es)
EA (1) EA021944B1 (es)
HN (1) HN2011003102A (es)
IL (1) IL215903A0 (es)
MA (1) MA33291B1 (es)
MX (1) MX2011012507A (es)
MY (1) MY166555A (es)
NZ (1) NZ596621A (es)
PE (1) PE20120402A1 (es)
SG (1) SG175759A1 (es)
TN (1) TN2011000596A1 (es)
TW (1) TWI464166B (es)
UA (1) UA107576C2 (es)
UY (1) UY32652A (es)
WO (1) WO2010136138A1 (es)
ZA (1) ZA201108609B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009014484A1 (de) 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
CA2851087C (en) 2011-10-07 2019-09-24 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
JP5900182B2 (ja) * 2012-06-21 2016-04-06 セントラル硝子株式会社 α，α−ジフルオロ芳香族化合物の製造方法
JP6197348B2 (ja) * 2013-04-25 2017-09-20 セントラル硝子株式会社 α，α−ジフルオロ芳香族化合物の保存安定性の向上方法
WO2026050288A1 (en) * 2024-08-26 2026-03-05 Research Institute At Nationwide Children's Hospital Modulating the acute foreign body reaction to reduce stenosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
WO1997036873A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US6403612B2 (en) 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
AU2002363369B2 (en) 2001-10-15 2008-08-21 Janssen Pharmaceutica N.V. Substituted 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
WO2006002349A1 (en) 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
US20060009491A1 (en) 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
EA200700117A1 (ru) 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
KR20070050076A (ko) 2004-08-10 2007-05-14 인사이트 산 디에고 인코포레이티드 아미도 화합물 및 약제로서의 이의 용도
DE102004042607A1 (de) * 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
EP1705960A1 (en) 2005-03-21 2006-09-27 IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. Electroluminescent lamp
EP1931652A2 (en) 2005-09-21 2008-06-18 Incyte Corporation Amido compounds and their use as pharmaceuticals
KR20080091503A (ko) 2006-01-31 2008-10-13 인사이트 코포레이션 아미도 화합물 및 약제로서의 이의 용도
US20070213311A1 (en) 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
US20070293529A1 (en) 2006-05-01 2007-12-20 Yun-Long Li Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
DE502008003324D1 (de) * 2007-11-30 2011-06-01 Bayer Schering Pharma Ag Heteroaryl-substituierte piperidine
DE102009014484A1 (de) 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022895A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022892A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022897A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine

Also Published As

Publication number Publication date
PE20120402A1 (es) 2012-04-18
HK1171450A1 (en) 2013-03-28
JP2012528089A (ja) 2012-11-12
CN102482270B (zh) 2015-02-25
MX2011012507A (es) 2011-12-14
MY166555A (en) 2018-07-16
AU2010252339B2 (en) 2014-10-23
UA107576C2 (ru) 2015-01-26
TN2011000596A1 (en) 2013-05-24
TWI464166B (zh) 2014-12-11
EA201190313A1 (ru) 2012-05-30
MA33291B1 (fr) 2012-05-02
US20130252948A1 (en) 2013-09-26
TW201107319A (en) 2011-03-01
CR20110627A (es) 2012-03-22
CU24011B1 (es) 2014-06-27
US8440657B2 (en) 2013-05-14
UY32652A (es) 2010-12-31
SG175759A1 (en) 2011-12-29
US20100305111A1 (en) 2010-12-02
CN102482270A (zh) 2012-05-30
AU2010252339A1 (en) 2011-12-08
CA2763386A1 (en) 2010-12-02
BRPI1012775A2 (pt) 2019-09-24
IL215903A0 (en) 2012-01-31
HN2011003102A (es) 2015-02-23
ZA201108609B (en) 2013-02-27
AR076709A1 (es) 2011-06-29
JP5728687B2 (ja) 2015-06-03
US8202862B2 (en) 2012-06-19
DE102009022894A1 (de) 2010-12-02
KR20120024652A (ko) 2012-03-14
WO2010136138A1 (de) 2010-12-02
CO6470822A2 (es) 2012-06-29
NZ596621A (en) 2013-12-20
EP2435431A1 (de) 2012-04-04
EA021944B1 (ru) 2015-10-30
US20120135985A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
UY31484A1 (es) Piperidinas heteroaril-sustituidas
ECSP11011483A (es) Piperidinas sustituidas
ECSP099581A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso
SV2011004019A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
ECSP14013224A (es) Pirimidinas anilladas sustituidas y uso de las mismas
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
DK3045456T3 (da) Bicyklisk substituerede uraciler og anvendelse heraf
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
CO6300844A2 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
CR20110627A (es) Piperidinas sustituidas
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
HK1202868A1 (en) Carboxamide-substituted heteroaryl-pyrazoles and the use thereof
UY35592A (es) Benzoxazoles sustituidos
DOP2005000223A (es) Nonadepsipeptidos acilados ii
UA111139C2 (uk) Тверді фармацевтичні композиції і способи їхнього отримання
CU20100181A7 (es) Derivados de (pirazolilcarbonil)imidazolidinonas para el tratamiento de enfermedades retrovirales

Legal Events

Date Code Title Description
FG Grant of patent